ING Group’s Realm Therapeutics plc American Depositary Shares RLM Stock Holding History

ING Group’s Portfolio RLM Stock Details RLM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-29,600	Closed	-$116K	–	876
2019 Q1	$116K	Buy	+29,600	New	+$83K	﹤0.01%	696

Other funds holding RLM

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

PSC

Piper Sandler & Co Minneapolis, Minnesota $135M AUM 0.15% 1-Year Est. Return

ING Group's RLM Position: Q2 2019 in Review

ING Group sold out of Realm Therapeutics plc American Depositary Shares (RLM) in Q2 2019, closing a stake of 29,600 shares — an estimated $116K sold.

ING Group first reported a position in RLM in Q1 2019 and held it in 1 quarter. The position peaked at $116K in Q1 2019. 7 funds tracked by Wall St. Rank hold RLM as of Q2 2019.

ING Group reported no remaining Realm Therapeutics plc American Depositary Shares position as of Q2 2019 after selling out during the quarter.
ING Group sold 29,600 Realm Therapeutics plc American Depositary Shares shares in Q2 2019, an estimated $116K.
ING Group first reported a position in Realm Therapeutics plc American Depositary Shares in Q1 2019 and held it in 1 quarter.
ING Group's Realm Therapeutics plc American Depositary Shares position peaked at $116K in Q1 2019.
7 funds tracked by Wall St. Rank held Realm Therapeutics plc American Depositary Shares as of Q2 2019.

Based on ING Group's 13F filing for Q2 2019, filed 12 Aug 2019.